Severe hypercalcemia due to metastatic pancreatic neuroendocrine tumor: a case report.
Hypercalcemia
Neuroendocrine tumor
PTHrP
Pancreas
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
06 Sep 2023
06 Sep 2023
Historique:
received:
13
03
2023
accepted:
15
06
2023
medline:
7
9
2023
pubmed:
6
9
2023
entrez:
5
9
2023
Statut:
epublish
Résumé
Hypercalcemia of malignancy, as a paraneoplastic syndrome, is the most common metabolic disorder that accounts for 30% of malignancies and usually has a poor prognosis. Neuroendocrine tumors are uncommon and arise from neuroendocrine cells throughout the body. Actually, paraneoplastic hypercalcemia in neuroendocrine tumors is unusual and mostly associated with parathyroid hormone-related protein (PTHrP) secretion. We report a 51-year-old Iranian man who presented with nausea, vomiting, and significant weight loss for 1 month. Laboratory data revealed calcium of 26 mg/dl, accompanied by low level of PTH. Octreotide scan revealed a large donut-shaped octreotide avid lesion in the epigastric region at the right side of the mid-abdomen, with multiple varying size foci of abnormally increased radiotracer uptake in the epigastric region and both lobes of the liver. Endoscopic ultrasonography demonstrated a large heterogeneous mass lesion with irregular outline and good demarcation in the body of the pancreas with diffuse foci of calcification. Percutaneous biopsy of the liver mass demonstrated a well-differentiated neuroendocrine tumor (low grade) confirmed by immunohistochemistry with strongly positive chromogranin and synaptophysin stain. Hypercalcemia was treated with hydration, few sessions of hemodialysis, calcitonin, and denosumab injection. However, the patient developed symptomatic hypocalcemia. Oncology consultation led to prescription of long-acting octreotide 30 mg monthly and everolimus daily. Pancreatic neuroendocrine tumor could lead to malignant hypercalcemia; secretion of PTHrP is the most common cause, and signs and symptoms are usually milder than paraneoplastic syndrome due to hematologic and solid tumor. Generally, survival is better; however, its treatment is challenging, and primary debulking surgery is often required. A team approach to management is important at all points.
Sections du résumé
BACKGROUND
BACKGROUND
Hypercalcemia of malignancy, as a paraneoplastic syndrome, is the most common metabolic disorder that accounts for 30% of malignancies and usually has a poor prognosis. Neuroendocrine tumors are uncommon and arise from neuroendocrine cells throughout the body. Actually, paraneoplastic hypercalcemia in neuroendocrine tumors is unusual and mostly associated with parathyroid hormone-related protein (PTHrP) secretion.
CASE PRESENTATION
METHODS
We report a 51-year-old Iranian man who presented with nausea, vomiting, and significant weight loss for 1 month. Laboratory data revealed calcium of 26 mg/dl, accompanied by low level of PTH. Octreotide scan revealed a large donut-shaped octreotide avid lesion in the epigastric region at the right side of the mid-abdomen, with multiple varying size foci of abnormally increased radiotracer uptake in the epigastric region and both lobes of the liver. Endoscopic ultrasonography demonstrated a large heterogeneous mass lesion with irregular outline and good demarcation in the body of the pancreas with diffuse foci of calcification. Percutaneous biopsy of the liver mass demonstrated a well-differentiated neuroendocrine tumor (low grade) confirmed by immunohistochemistry with strongly positive chromogranin and synaptophysin stain. Hypercalcemia was treated with hydration, few sessions of hemodialysis, calcitonin, and denosumab injection. However, the patient developed symptomatic hypocalcemia. Oncology consultation led to prescription of long-acting octreotide 30 mg monthly and everolimus daily.
CONCLUSION
CONCLUSIONS
Pancreatic neuroendocrine tumor could lead to malignant hypercalcemia; secretion of PTHrP is the most common cause, and signs and symptoms are usually milder than paraneoplastic syndrome due to hematologic and solid tumor. Generally, survival is better; however, its treatment is challenging, and primary debulking surgery is often required. A team approach to management is important at all points.
Identifiants
pubmed: 37670372
doi: 10.1186/s13256-023-04042-5
pii: 10.1186/s13256-023-04042-5
pmc: PMC10481486
doi:
Substances chimiques
Parathyroid Hormone-Related Protein
0
Octreotide
RWM8CCW8GP
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
400Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Kaltsas G, Androulakis II, de Herder WW, Grossman AB. Paraneoplastic syndromes secondary to neuroendocrine tumours. Endocr Relat Cancer. 2010;17(3):R173.
doi: 10.1677/ERC-10-0024
pubmed: 20530594
Dimitriadis GK, Angelousi A, Weickert MO, Randeva HS, Kaltsas G, Grossman A. Paraneoplastic endocrine syndromes. Endocr Relat Cancer. 2017;24(6):R173–90.
doi: 10.1530/ERC-17-0036
pubmed: 28341725
Asonitis N, Angelousi A, Zafeiris C, Lambrou GI, Dontas I, Kassi E. Diagnosis, pathophysiology and management of hypercalcemia in malignancy: a review of the literature. Horm Metab Res. 2019;51(12):770–8.
doi: 10.1055/a-1049-0647
pubmed: 31826272
Santarpia L, Koch C, Sarlis N. Hypercalcemia in cancer patients: pathobiology and management. Horm Metab Res. 2010;42(03):153–64.
doi: 10.1055/s-0029-1241821
pubmed: 19960404
Stewart AF. Hypercalcemia associated with cancer. N Engl J Med. 2005;352(4):373–9.
doi: 10.1056/NEJMcp042806
pubmed: 15673803
Rosner MH, Dalkin AC. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia. Clin J Am Soc Nephrol. 2012;7(10):1722–9.
doi: 10.2215/CJN.02470312
pubmed: 22879438
Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocaña A, Stewart AF. Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36)[hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab. 2003;88(4):1603–9.
doi: 10.1210/jc.2002-020773
pubmed: 12679445
Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25(3):458–511.
doi: 10.1210/er.2003-0014
pubmed: 15180952
Gaudenzi G, Dicitore A, Carra S, Saronni D, Pozza C, Giannetta E, et al. Management of endocrine disease: precision medicine in neuroendocrine neoplasms: an update on current management and future perspectives. Eur J Endocrinol. 2019;181(1):R1–10.
doi: 10.1530/EJE-19-0021
pubmed: 31048562
Daskalakis K, Chatzelis E, Tsoli M, Papadopoulou-Marketou N, Dimitriadis GK, Tsolakis AV, et al. Endocrine paraneoplastic syndromes in patients with neuroendocrine neoplasms. Endocrine. 2019;64(2):384–92.
doi: 10.1007/s12020-018-1773-3
pubmed: 30280284
Kamp K, Feelders RA, van Adrichem RC, de Rijke YB, van Nederveen FH, Kwekkeboom DJ, et al. Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up. J Clin Endocrinol Metab. 2014;99(9):3060–9.
doi: 10.1210/jc.2014-1315
pubmed: 24905065
Tsoli M, Dimitriadis GK, Androulakis II, Kaltsas G, Grossman A. Paraneoplastic syndromes related to neuroendocrine tumors. Endotext [Internet]. 2020.
Giannetta E, Sesti F, Modica R, Grossrubatscher EM, Ragni A, Zanata I, et al. What lies behind paraneoplastic hypercalcemia secondary to well-differentiated neuroendocrine neoplasms? A systematic review of the literature. J Personalized Med. 2022;12(10):1553.
doi: 10.3390/jpm12101553
Weiss ES, Doty J, Brock MV, Halvorson L, Yang SC. A case of ectopic parathyroid hormone production by a pulmonary neoplasm. J Thorac Cardiovasc Surg. 2006;131(4):923–4.
doi: 10.1016/j.jtcvs.2005.12.020
pubmed: 16580460
van Lierop AH, Bisschop PH, Boelen A, van Eeden S, Engelman AF, Nieveen van Dijkum EJ, et al. Hypercalcaemia due to a calcitriol-producing neuroendocrine tumour. J Surg Case Rep. 2019;2019(12):rjz346.
doi: 10.1093/jscr/rjz346
pubmed: 31832136
pmcid: 6900336
Zhu V, de Las MA, Janicek M, Hartshorn K. Hypercalcemia from metastatic pancreatic neuroendocrine tumor secreting 1,25-dihydroxyvitamin D. J Gastrointest Oncol. 2014;5(4):E84.
pubmed: 25083313
pmcid: 4110490
Giannetta E, Sesti F, Modica R, Grossrubatscher EM, Guarnotta V, Ragni A, et al. Case report: unmasking hypercalcemia in patients with neuroendocrine neoplasms. Experience from six italian referral centers. Front Endocrinol. 2021;12:665698.
doi: 10.3389/fendo.2021.665698
Gild ML, Tsang V, Samra J, Clifton-Bligh RJ, Tacon L, Gill AJ. Hypercalcemia in glucagon cell hyperplasia and neoplasia (Mahvash syndrome): a new association. J Clin Endocrinol Metab. 2018;103(9):3119–23.
doi: 10.1210/jc.2018-01074
pubmed: 30032256
Rossi RE, Naik K, Navalkissoor S, Imber C, O’Beirne J, Toumpanakis C, et al. Case report of multimodality treatment for metastatic parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumour. Tumori J. 2014;100(4):e153–6.
doi: 10.1177/1636.17936
Papazachariou I, Virlos I, Williamson R. Parathyroid hormone-related peptide in pancreatic neuroendocrine tumours associated with hypercalcaemia. HPB. 2001;3(3):221–5.
doi: 10.1080/136518201753242253
pubmed: 18333019
pmcid: 2020623
DeWys WD, Stoll R, Au WY, Salisnjak MM. Effects of streptozotocin on an islet cell carcinoma with hypercalcemia. Am J Med. 1973;55(5):671–6.
doi: 10.1016/0002-9343(73)90190-3
pubmed: 4356099
Mullerpatan PM, Joshi SR, Shah RC, Tampi CS, Doctor VM, Jagannath P, et al. Calcitonin-secreting tumor of the pancreas. Dig Surg. 2004;21(4):321–4.
doi: 10.1159/000080901
pubmed: 15375334
Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990–3011.
doi: 10.1210/jc.2012-1230
pubmed: 22723327
WellsSamuel Jr A, AsaSylvia L, EvansDouglas B, GagelRobert F, MoleyJeffrey F, Sara R, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015.
Kanakis G, Kaltsas G, Granberg D, Grimelius L, Papaioannou D, Tsolakis AV, et al. Unusual complication of a pancreatic neuroendocrine tumor presenting with malignant hypercalcemia. J Clin Endocrinol Metab. 2012;97(4):E627–31.
doi: 10.1210/jc.2011-2592
pubmed: 22319031
Schuerheck K, Madarasz Z, Hiller W. Malignant hypercalcemia caused by Pthrp-Secreting pancreatic neuroendocrine tumor (Pnet)-diagnosis and treatment of a very rare tumor entity. HPB. 2021;23:S247.
doi: 10.1016/j.hpb.2020.11.622
John Allendorf JC. Surgical resection of sporadic pancreatic neuroendocrine tumors. 2022.
Kim B, Prakash L, Ikoma N, Kim M, Tzeng C-W, Vauthey J, et al. Surgical resection of sporadic pancreatic neuroendocrine tumors: a two-decade experience at a large volume cancer center. HPB. 2022;24:S398–9.
doi: 10.1016/j.hpb.2022.05.846
Milanesi A, Yu R, Geller SA, Burton D, Deftos LJ, Wolin EM. Concurrent primary hyperparathyroidism and humoral hypercalcemia of malignancy in a patient with multiple endocrine neoplasia type 1. Pancreas. 2011;40(4):634–7.
doi: 10.1097/MPA.0b013e318214f65e
pubmed: 21483254
Burgess J, Wilkinson S, Lowenthal R. Parathyroid hormone related protein (PTHrP) mediated hypercalcaemia complicating enteropancreatic malignancy in multiple endocrine neoplasia type 1 (MEN 1). Aust N Z J Med. 2000;30(2):280–1.
doi: 10.1111/j.1445-5994.2000.tb00824.x
pubmed: 10833127
Clemens P, Gregor M, Lamberts R. Pancreatic neuroendocrine tumor with extensive vascularisation and parathyroid hormone-related protein (PTHrP)-associated hypercalcemia of malignancy. Exp Clin Endocrinol Diabetes. 2001;109(07):378–85.
doi: 10.1055/s-2001-17411
pubmed: 11573150
Shah RH, Martinez D. Pancreatic neuroendocrine tumor associated with humoral hypercalcemia of malignancy and carcinoid tumor: a case report and review of the literature. Pancreas. 2013;42(3):549–51.
doi: 10.1097/MPA.0b013e318267c987
pubmed: 23211368
Öberg K, Kvols L, Caplin M, DelleFave G, de Herder W, Rindi G, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15(6):966–73.
doi: 10.1093/annonc/mdh216
pubmed: 15151956
Sidéris L, Dubé P, Rinke A. Antitumor effects of somatostatin analogs in neuroendocrine tumors. Oncologist. 2012;17(6):747–55.
doi: 10.1634/theoncologist.2011-0458
pubmed: 22628056
pmcid: 3380872
Nachawi N, Paredes S, Seibert S, McShane A, Pantalone KM. Extreme secretion of PTHrP from a pancreatic neuroendocrine tumor, a shift from severe hypercalcemia to hypocalcemia. J Endocr Soc. 2021;5(Suppl 1):A192.
doi: 10.1210/jendso/bvab048.391
pmcid: 8089201
Valdes-Socin H, Almanza MR, Fernández-Ladreda MT, Daele DV, Polus M, Chavez M, et al. Use of cinacalcet and sunitinib to treat hypercalcaemia due to a pancreatic neuroendocrine tumor. Arch Endocrinol Metab. 2017;61:506–9.
doi: 10.1590/2359-3997000000291
pubmed: 28977163
pmcid: 10522250
Karaca H, Lale A, Dikilitas M, Ozkan M, Er O. Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature. Med Oncol. 2010;27(3):1023–6.
doi: 10.1007/s12032-009-9327-4
pubmed: 19830602